ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer-Reference-Cited by-同舟云学术

ADAM 17 selectively activates the IL ‐6 trans‐signaling/ ERK MAPK axis in KRAS ‐addicted lung cancer

Published:2019-03-04 Issue:4 Volume:11 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Saad Mohamed I¹²^ORCID,Alhayyani Sultan¹²,McLeod Louise¹²,Yu Liang¹²,Alanazi Mohammad¹²,Deswaerte Virginie¹²,Tang Ke¹²,Jarde Thierry³⁴⁵,Smith Julian A⁶⁷,Prodanovic Zdenka⁸,Tate Michelle D¹²,Balic Jesse J¹²,Watkins D Neil⁹,Cain Jason E²⁵,Bozinovski Steven¹⁰,Algar Elizabeth⁵¹¹,Kohmoto Tomohiro¹²¹³,Ebi Hiromichi¹⁴¹⁵,Ferlin Walter¹⁶,Garbers Christoph¹⁷,Ruwanpura Saleela¹²,Sagi Irit¹⁸,Rose‐John Stefan¹⁹,Jenkins Brendan J¹²^ORCID

Affiliation:

1. Centre for Innate Immunity and Infectious Diseases Hudson Institute of Medical Research Clayton Vic. Australia

2. Department of Molecular and Translational Sciences Faculty of Medicine, Nursing and Health Sciences Monash University Clayton Vic. Australia

3. Cancer Program, Monash Biomedicine Discovery Institute Clayton Vic. Australia

4. Department of Anatomy and Developmental Biology Monash University Clayton Vic. Australia

5. Centre for Cancer Research Hudson Institute of Medical Research Clayton Vic. Australia

6. Department of Surgery School of Clinical Sciences at Monash Health Monash University Clayton Vic. Australia

7. Department of Cardiothoracic Surgery Monash Health Clayton Vic. Australia

8. Monash Biobank Monash Health Clayton Vic. Australia

9. The Kinghorn Cancer Centre Garvan Institute of Medical Research Darlinghurst NSW Australia

10. School of Health and Biomedical Sciences RMIT University Bundoora Vic. Australia

11. Genetics and Molecular Pathology Laboratory Monash Health Clayton Vic. Australia

12. Department of Human Genetics Tokushima University Graduate School of Medicine Tokushima Japan

13. Division of Molecular Genetics Aichi Cancer Center Research Institute Nagoya Japan

14. Division of Molecular Therapeutics Aichi Cancer Center Research Institute Nagoya Japan

15. Division of Advanced Cancer Therapeutics Nagoya University Graduate School of Medicine Nagoya Japan

16. NovImmune SA Geneva Switzerland

17. Department of Pathology Medical Faculty Otto‐von‐Guericke University Magdeburg Germany

18. Department of Biological Regulation Weizmann Institute of Science Rehovot Israel

19. Institute of Biochemistry Christian‐Albrechts‐University Kiel Germany

Funder

Deutsche Forschungsgemeinschaft

National Health and Medical Research Council

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.201809976

Reference63 articles.

1. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung

2. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma

3. EGF Receptor Is Required for KRAS-Induced Pancreatic Tumorigenesis

4. ADAM17 Regulates Epidermal Growth Factor Receptor Expression through the Activation of Notch1 in Non–Small Cell Lung Cancer

5. IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ginsenoside CK ameliorates tumor growth in lung cancer mice via inhibiting EGFR;Journal of Functional Foods;2024-10

2. The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS‐CoV‐2 infection in cultured human lung cells;BioFactors;2024-06-17

3. BIRC3–HSP90B1 Interaction Inhibits Non-Small Cell Lung Cancer Progression through the Extracellular Signal-Regulated Kinase Pathway;ACS Omega;2024-04-16

4. Cytosolic DNA sensor AIM2 promotes KRAS‐driven lung cancer independent of inflammasomes;Cancer Science;2024-04-09

5. Navigating IL-6: From molecular mechanisms to therapeutic breakthroughs;Cytokine & Growth Factor Reviews;2024-04